◆英語タイトル:Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA8011658
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月12日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Dynavax Technologies Corp (DVAX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Dynavax Technologies Corp (Dynavax), formerly Double Helix Corp, is a clinical-stage biopharmaceutical company that develops product candidates for the prevention of infectious and inflammatory disease. The company’s only marketed product HEPLISAV-B is an adult vaccine for hepatitis B. Its pipeline includes AZD1419, a drug for the treatment of asthma; DV281, an agonist which focuses on lung tumors and lung metastases; and SD-101, an agonist focusing on immune response to various cancers. Dynavax’s pre-clinical pipeline encompasses DV230F for liver tumors, DV1001 for multiple malignancies.The company develops immunotherapies based on toll-like receptor technology for the treatment and prevention of infectious and inflammatory diseases and cancer. It has subsidiary in Germany. Dynavax is headquartered in Berkeley, California, the US.
Dynavax Technologies Corp Key Recent Developments
Nov 03,2017: Dynavax Reports Third Quarter 2017 Financial Results
Aug 02,2017: Dynavax Reports Second Quarter 2017 Financial Results
Jun 21,2017: Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
May 08,2017: Dynavax Reports First Quarter 2017 Financial Results
Mar 13,2017: Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Dynavax Technologies Corp – Key Facts 5
Dynavax Technologies Corp – Key Employees 6
Dynavax Technologies Corp – Major Products and Services 7
Dynavax Technologies Corp – History 8
Dynavax Technologies Corp – Company Statement 9
Dynavax Technologies Corp – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Dynavax Technologies Corp – Business Description 13
R&D Overview 13
Dynavax Technologies Corp – SWOT Analysis 14
SWOT Analysis – Overview 14
Dynavax Technologies Corp – Strengths 14
Dynavax Technologies Corp – Weaknesses 15
Dynavax Technologies Corp – Opportunities 16
Dynavax Technologies Corp – Threats 17
Dynavax Technologies Corp – Key Competitors 18
Section 3 – Company Financial Ratios 19
Financial Ratios – Capital Market Ratios 19
Financial Ratios – Annual Ratios 20
Performance Chart 22
Financial Performance 22
Financial Ratios – Interim Ratios 23
Financial Ratios – Ratio Charts 24
Section 4 – Company’s Lifesciences Financial Deals and Alliances 25
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 27
Dynavax Technologies Corp, Recent Deals Summary 28
Section 5 – Company’s Recent Developments 29
Nov 03, 2017: Dynavax Reports Third Quarter 2017 Financial Results 29
Aug 02, 2017: Dynavax Reports Second Quarter 2017 Financial Results 30
Jun 21, 2017: Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance 31
May 08, 2017: Dynavax Reports First Quarter 2017 Financial Results 32
Mar 13, 2017: Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update 33
Nov 07, 2016: Dynavax Reports Third Quarter 2016 Financial Results and Company Update 35
Aug 05, 2016: Dynavax Reports Second Quarter 2016 Financial Results 36
May 09, 2016: Dynavax Reports First Quarter 2016 Financial Results 37
Mar 08, 2016: Dynavax Reports Fourth Quarter and Year End 2015 Financial Results 38
Section 6 – Appendix 39
Methodology 39
Ratio Definitions 39
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Tables
Dynavax Technologies Corp, Key Facts 5
Dynavax Technologies Corp, Key Employees 6
Dynavax Technologies Corp, Major Products and Services 7
Dynavax Technologies Corp, History 8
Dynavax Technologies Corp, Subsidiaries 12
Dynavax Technologies Corp, Key Competitors 18
Dynavax Technologies Corp, Ratios based on current share price 19
Dynavax Technologies Corp, Annual Ratios 20
Dynavax Technologies Corp, Annual Ratios (Cont...1) 21
Dynavax Technologies Corp, Interim Ratios 23
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 27
Dynavax Technologies Corp, Recent Deals Summary 28
Currency Codes 39
Capital Market Ratios 39
Equity Ratios 40
Profitability Ratios 40
Cost Ratios 41
Liquidity Ratios 41
Leverage Ratios 42
Efficiency Ratios 42